Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

First total synthesis of (±)-sanggenon F and its osteogenic differentiation promoting activity on human mesenchymal stem cells.

Ma RF., Jing Y., Song H., Wang B., Li J., Yin XS.

Laboratory Study, published in Nat Prod Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Nat Prod Res (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41021979
DOI
10.1080/14786419.2025.2565815

Abstract (original English)

Sanggenon F is a flavanone-type natural product with different bioactivities, but its total synthesis has never been reported. In the present study, the first total synthesis of (±)-sanggenon F was accomplished in ten steps and 2.4% overall yield, involving two key reactions of the Aldol condensation and oxa-Michael addition. The promoting activity of (±)-sanggenon F on the osteogenic differentiation of human umbilical cord-derived mesenchymal stem cells (MSC) and human adipose-derived MSC was assessed via alkaline phosphatase staining and alizarin red S staining. Excitingly, (±)-sanggenon F displayed significant osteogenic differentiation promoting effect towards both cell lines and it might be used as a template molecule for the future design and development of adjuvant drugs in MSC therapy.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.